Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 4, 2002, Pages 385-396

  Orlova, Anna ^a   Hoöglund, Johanna ^a   Lubberink, Mark ^a   Lebeda, Ondrej ^b   Gedda, Lars ^a   Lundqvist, Hans ^a   Tolmachev, Vladimir ^a   Sundin, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NUCLEAR PHYSICS INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE; BROMINE DERIVATIVE; IODINE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; NONHUMAN; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RAT; SCINTILLATION CAMERA; SPLEEN; STOMACH; THYROID GLAND; X RAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; BROMINE RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; RADIOIMMUNOTHERAPY; RADIOMETRY; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036380194     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760363187     Document Type: Article

References (39)

1. Vaidyanathan G and Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol 1996;41:1915-1931.
2. Juweid M, Sharkey RM, Swayne LC et al. Pharmaco-kinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med 1998;39:34-42.
3. Behr TM, Sharkey RM, Juweid ME et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858-870.
4. Lundqvist H, Lubberink M and Tolmachev V. Positron emission tomography. Eur J Phys 1998;19:537-552.
5. Sgouros G, Ballangrud AM, Jurcic JG et al. Pharmaco-kinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-1946.
6. Kotzerke J, Glatting G, Seitz U et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re-and 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med 2000;41:531-537.
7. Cremonesi M, Ferrari M, Chinol M et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110-120.
8. DeNardo SJ, Kramer EL, O'Donnell RT et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997;38:1180-1185.
9. 131I-and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Canc Res 1999;5:3292s-3303s.
10. Richman CM, DeNardo SJ, O'Donnell RT et al. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Canc Res 1999;5:3243s-3248s.
11. 131I as labels of a monoclonal antibody and F(ab′)2 fragment. Cancer Res 1990;50:3514-3520.
12. Hadley SW, Wilbur DS, Gray MA and Atcher RW. Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate. Bioconjug Chem 1991;2:171-179.
13. Reist CJ, Foulon CF, Alston K et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol 1999;26:405-411.
14. Wilbur DS, Vessella RL, Stray JE et al. Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab′)2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab′)2. Nucl Med Biol 1993;20: 917-927.
15. Zalutsky MR, Stabin MG, Larsen RH and Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nucl Med Biol 1997;24: 255-261.
16. Westera G, Reist HW, Buchegger F et al. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl Med Commun 1991;12:429-437.
17. Scholten B, Kovacs Z, Tarkanyi F and Qaim SM. Excitation functions of 124Te(p, xn)124, 123I reactions from 6 to 31 MeV with special reference to the production of 124I at a small cyclotron. Appl Radiat Isot 1995;46:255-259.
18. 76Br by a low-energy cyclotron. Appl Radiat Isot 1998;49:1537-1540.
19. 76Br-labelled monoclonal antibodies for PET. Preclinical evaluation of halogenated antibodies for diagnosis and treatment of cancer. Comprehensive Summaries of Uppsala Disertations from the Faculty of Medicine. Uppsala University, Uppsala, Sweden, 2002.
20. Ritter G, Cohen LS, Nice EC et al. Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem Biophys Res Commun 1997;236:682-686.
21. Garin-Chesa P, Sakamoto J, Welt S et al. Organ-Specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncology 1996;9:465-471.
22. 124I-cdr-grafted humanized A33 monoclonal antibody. J Nucl Med 2001;42:764-769.
23. Moritz RL, Ritter G, Catimel B et al. Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium. J Chromatogr 1998;A 798:91-101.
24. Daghighian F, Barendswaard E, Welt S et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 1996;37:1052-1057.
25. Orlova A, Sjöström A, Lebeda O, Lundqvist H, Carlsson J and Tolmachev V. Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. In Sjöström A. Radionuclide targeting with particular emphasis on urinary bladder carcinoma. Comprehensive Summaries of Uppsala Disertations from the Faculty of Medicine. Uppsala University, Uppsala, Sweden, 2001.
26. Orlova A, Bruskin A, Sjöström A et al. Cellular processing of (125)I- and (111)In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl Med Biol 2000;27:827-835.
27. Browne E and Firestone R. In: Shirley VS ed. Section III, Table of Radioactive Isotopes. John Wiley and Sons, New York, 1986.
28. Visser GW, Diemer EL and Kaspersen FM. The nature of astatine-protein bound. Int J Appl Radiat Isot 1981;32:905-912.
29. 14C-urea and development of dosimetric models. Department of Radiation Physics, University of Lund, Malmö, Sweden, 1999.
30. Pentlow KS, Graham MC, Lambrecht RM et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996;37:1557-1562.
31. Turkington TG, Zalutsky MR, Jaszczak RJ et al. Measuring astatine-211 distributions with SPECT. Phys Med Biol 1993;38:1121-1130.
32. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol 1995;22:45-54.
33. Wilbur DS, Hadley SW, Hylarides MD et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 1989;30:216-226.
34. Zalutsky MR and Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Int J Rad Appl Instrum [A] 1987;38:1051-1055.
35. Zalutsky MR and Narula AS. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. Cancer Res 1988; 48:1446-1450.
36. Zalutsky MR, Noska MA, Colapinto EV et al. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(trin-butylstannyl)benzoate. Cancer Res 1989;49:5543-5549.
37. Lovqvist A, Sundin A, Ahlström H et al. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J Nucl Med 1997;38:395-401.
38. Larsen RH, Slade S and Zalutsky MR. Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. Nucl Med Biol 1998;25:351-357.
39. Zalutsky MR and Vaidyanathan J. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Design 2000;6: 1433-1455.